Company Profile

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing precision medicines for kidney diseases. Its lead product candidate is atrasentan, a potent and selective endothelin A receptor (ET A receptor), antagonist that is developing for the treatment of proteinuric glomerular diseases. Atrasentan is in Phase III trials for the treatment of IgA nephropathy (IgAN) and proteinuric glomerular diseases. Its second product candidate, BION-1301, is an anti-APRIL monoclonal antibody also in Phase II development for patients with IgAN. Its third product candidate, CHK-336, is an oral small molecule lactate dehydrogenase (LDHA), inhibitor for the treatment of primary and idiopathic hyperoxaluria that is in a Phase I clinical trial in healthy volunteers. In addition, the Company is also conducting research programs in several other rare, severe chronic kidney diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

04-21	Rigetti & Co, LLC Enters Sublease Agreement with Chinook Therapeutics, Inc	CI
23-08-11	Chinook Therapeutics, Inc. Announces Board Cessations	CI
23-08-11	Novartis Says it Completed Chinook Therapeutics Acquisition	MT
23-08-11	Novartis Completes Acquisition of Chinook Therapeutics for Up to $3.5 Billion	MT
23-08-11	Chinook Therapeutics, Inc.(NasdaqGM:KDNY) dropped from NASDAQ Composite Index	CI
23-08-10	Novartis AG completed the acquisition of Chinook Therapeutics, Inc. from a group of shareholders.	CI
23-08-10	Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P Global BMI Index	CI
23-08-10	Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index	CI
23-08-10	Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P Biotechnology Select Industry Index	CI
23-08-09	Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index	CI
23-08-08	Wedbush Downgrades Chinook Therapeutics to Neutral From Outperform as Sale to Novartis Draws Closer; Keeps $42 Price Target	MT
23-08-07	Chinook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-08-01	Wells Fargo Downgrades Chinook Therapeutics to Equalweight From Overweight, Adjusts Price Target to $40 From $30	MT

23-08-08	Wedbush Downgrades Chinook Therapeutics to Neutral From Outperform as Sale to Novartis Draws Closer; Keeps $42 Price Target	MT
23-08-01	Wells Fargo Downgrades Chinook Therapeutics to Equalweight From Overweight, Adjusts Price Target to $40 From $30	MT
23-08-01	Analyst recommendations: Meta, Thermo Fisher, Union Pacific, Domino's Pizza...
23-06-14	Evercore ISI Downgrades Chinook Therapeutics to In Line From Outperform, Price Target is $40	MT
23-06-13	Stifel Downgrades Chinook Therapeutics to Hold From Buy, Adjusts Price Target to $41 From $43	MT

23-09-18	Focal Segmental Glomerulosclerosis Pipeline, Clinical Trials Assessment, and NDA Approvals 2023 (Updated)	AQ
23-08-14	Novartis Completes Acquisition of Chinook Therapeutics	AQ
23-08-08	Chinook: Q2 Earnings Snapshot	AQ
23-07-28	Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy	AQ
23-07-21	CHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook Therapeutics, Inc. - KDNY	BU

23-08-14	EN DIRECTO DESDE LOS MERCADOS: Philips, Renault, Novartis, Pernod Ricard, Valneva, SoftBank, Country Garden, Shell...
23-08-14	Bolsa de Madrid: La renta variable sube, pero no los tipos
23-08-14	Aktien Schweiz Vorbörse: SMI im Rückwärtsgang erwartet
23-08-14	En direct des marchés : Renault, Pernod Ricard, Valneva, SoftBank, Country Garden, Shell...
23-08-14	Les actions plafonnent, mais pas les taux

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/11/23	Andrew Oxtoby	Issuer sale	Chief Commercial Officer	200,000	0.2785%
8/11/23	Eric Bjerkholt	Issuer sale	Chief Financial Officer	440,576	0.6136%
8/11/23	Tom Frohlich	Issuer sale	Founder	654,866	0.9120%

Chinook Therapeutics, Inc. Stock

Stocks

KDNY

US16961L1061

Biotechnology & Medical Research

Latest news : Chinook Therapeutics, Inc.

Analysts' recommendations: Chinook Therapeutics, Inc.

Press Releases: Chinook Therapeutics, Inc.

News in other languages: Chinook Therapeutics, Inc.

Quotes and Performance

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINOOK THERAPEUTICS, INC.	+0.22%	+0.25%	-	-	2.9B
ARGENX SE	+0.21%	-0.79%	+53.17%	+57.39%	53.79B
WUXI APPTEC CO., LTD.	+5.37%	+3.31%	+50.39%	+83.65%	54.69B
INSMED INCORPORATED	-1.20%	-1.94%	+4.35%	+402.68%	23.2B
BIONTECH SE	+0.74%	+2.32%	-16.23%	-14.44%	23.31B
WUXI BIOLOGICS (CAYMAN) INC.	+0.21%	+0.37%	+36.93%	-5.80%	20.03B
GENMAB A/S	-1.18%	-2.97%	+30.12%	-33.30%	17.31B
PHARMAESSENTIA CORPORATION	-1.67%	-6.00%	+163.95%	+284.69%	14.99B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.83%	+0.32%	+32.36%	+570.87%	15.36B
EXELIXIS, INC.	-0.70%	-0.91%	+24.87%	+179.47%	13.96B
Average	+0.12%	-0.71%	+42.21%	+169.47%	26.29B
Weighted average by Cap.	+0.97%	-0.93%	+41.84%	+133.20%